270 related articles for article (PubMed ID: 18397155)
21. [Value of prognostic factors in the Austrian A-NB87 Neuroblastoma Study].
Ladenstein R; Ambros PF; Urban C; Ambros IM; Fink FM; Zoubek A; Grienberger H; Schmitt K; Kerbl R; Horcher E; Amann G; Höfler G; Heinzl H; Gadner H; Mutz I
Klin Padiatr; 1996; 208(4):210-20. PubMed ID: 8926686
[TBL] [Abstract][Full Text] [Related]
22. Expressions of N-myc and ras oncogene products in neuroblastoma and their correlations with prognosis.
Nakada K; Fujioka T; Kitagawa H; Takakuwa T; Yamate N
Jpn J Clin Oncol; 1993 Jun; 23(3):149-55. PubMed ID: 8350488
[TBL] [Abstract][Full Text] [Related]
23. Primary germ cell tumors of the mediastinum: III. Yolk sac tumor, embryonal carcinoma, choriocarcinoma, and combined nonteratomatous germ cell tumors of the mediastinum--a clinicopathologic and immunohistochemical study of 64 cases.
Moran CA; Suster S; Koss MN
Cancer; 1997 Aug; 80(4):699-707. PubMed ID: 9264353
[TBL] [Abstract][Full Text] [Related]
24. Proliferation marker KI-S5 discriminates between favorable and adverse prognosis in advanced stages of neuroblastoma with and without MYCN amplification.
Krams M; Hero B; Berthold F; Parwaresch R; Harms D; Rudolph P
Cancer; 2002 Feb; 94(3):854-61. PubMed ID: 11857322
[TBL] [Abstract][Full Text] [Related]
25. Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma.
Horibe K; Fukuda M; Miyajima Y; Matsumoto K; Kondo M; Inaba J; Miyashita Y
Med Pediatr Oncol; 2001 Jan; 36(1):203-4. PubMed ID: 11464885
[TBL] [Abstract][Full Text] [Related]
26. Detection of n-myc gene amplification in neuroblastoma by comparative, in situ,and real-time polymerase chain reaction.
Melegh Z; Bálint I; Tóth E; Csernák E; Szentirmay Z; Nagy K
Pediatr Pathol Mol Med; 2003; 22(3):213-22. PubMed ID: 12746172
[TBL] [Abstract][Full Text] [Related]
27. Retrospective study on amplification of N-myc and c-myc genes in pediatric solid tumors and its association with prognosis and tumor differentiation.
Tsuda H; Shimosato Y; Upton MP; Yokota J; Terada M; Ohira M; Sugimura T; Hirohashi S
Lab Invest; 1988 Sep; 59(3):321-7. PubMed ID: 3411933
[TBL] [Abstract][Full Text] [Related]
28. Detection of N-myc oncogene expression in human neuroblastoma by in situ hybridization and blot analysis: relationship to clinical outcome.
Grady-Leopardi EF; Schwab M; Ablin AR; Rosenau W
Cancer Res; 1986 Jun; 46(6):3196-9. PubMed ID: 2421891
[TBL] [Abstract][Full Text] [Related]
29. Inverse correlation between expression of multidrug resistance gene and N-myc oncogene in human neuroblastomas.
Nakagawara A; Kadomatsu K; Sato S; Kohno K; Takano H; Akazawa K; Nose Y; Kuwano M
Cancer Res; 1990 May; 50(10):3043-7. PubMed ID: 2185879
[TBL] [Abstract][Full Text] [Related]
30. Clinical appearance of neuroblastoma 10 years after screening.
Kerbl R; Urban CE; Zotter H; Lackner H; Sovinz P; Ambros PF
Pediatr Blood Cancer; 2007 Dec; 49(7):1012-4. PubMed ID: 16534792
[TBL] [Abstract][Full Text] [Related]
31. Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience.
Canete A; Gerrard M; Rubie H; Castel V; Di Cataldo A; Munzer C; Ladenstein R; Brichard B; Bermúdez JD; Couturier J; de Bernardi B; Pearson AJ; Michon J
J Clin Oncol; 2009 Mar; 27(7):1014-9. PubMed ID: 19171715
[TBL] [Abstract][Full Text] [Related]
32. Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.
von Hoff K; Hartmann W; von Bueren AO; Gerber NU; Grotzer MA; Pietsch T; Rutkowski S
Pediatr Blood Cancer; 2010 Mar; 54(3):369-76. PubMed ID: 19908297
[TBL] [Abstract][Full Text] [Related]
33. Multifocal neuroblastoma: biologic behavior and surgical aspects.
Hiyama E; Yokoyama T; Hiyama K; Yamaoka H; Matsuura Y; Nishimura Si; Ueda K
Cancer; 2000 Apr; 88(8):1955-63. PubMed ID: 10760774
[TBL] [Abstract][Full Text] [Related]
34. Basaloid squamous cell carcinoma of the sinonasal tract.
Wieneke JA; Thompson LD; Wenig BM
Cancer; 1999 Feb; 85(4):841-54. PubMed ID: 10091761
[TBL] [Abstract][Full Text] [Related]
35. Expression of pan-neuroendocrine proteins in 53 neuroblastic tumors. An immunohistochemical study with neuron-specific enolase, chromogranin, and synaptophysin.
Hachitanda Y; Tsuneyoshi M; Enjoji M
Arch Pathol Lab Med; 1989 Apr; 113(4):381-4. PubMed ID: 2495784
[TBL] [Abstract][Full Text] [Related]
36. Neuroblastoma in southern Africa: epidemiological features, prognostic factors and outcome.
Hesseling PB; Ankone K; Wessels G; Schneider JW; Du Plessis L; Moore S
Ann Trop Paediatr; 1999 Dec; 19(4):357-63. PubMed ID: 10716030
[TBL] [Abstract][Full Text] [Related]
37. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis.
Shimada H; Stram DO; Chatten J; Joshi VV; Hachitanda Y; Brodeur GM; Lukens JN; Matthay KK; Seeger RC
J Natl Cancer Inst; 1995 Oct; 87(19):1470-6. PubMed ID: 7674334
[TBL] [Abstract][Full Text] [Related]
38. Association of N-myc amplification with neuroblastoma: the Australian and New Zealand experience.
Telford DJ; Kavallaris M; White L; Norris MD; Brian MJ; Stewart BW
J Paediatr Child Health; 1992 Feb; 28(1):58-63. PubMed ID: 1554517
[TBL] [Abstract][Full Text] [Related]
39. Clinical, biologic, and prognostic differences on the basis of primary tumor site in neuroblastoma: a report from the international neuroblastoma risk group project.
Vo KT; Matthay KK; Neuhaus J; London WB; Hero B; Ambros PF; Nakagawara A; Miniati D; Wheeler K; Pearson AD; Cohn SL; DuBois SG
J Clin Oncol; 2014 Oct; 32(28):3169-76. PubMed ID: 25154816
[TBL] [Abstract][Full Text] [Related]
40. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
